89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)
89Zr-TLX300-101
Phase 1 small_molecule active
Quick answer
89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx) for Soft Tissue Sarcoma is a Phase 1 program (small_molecule) at Telix Pharmaceuticals Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Telix Pharmaceuticals Ltd
- Indication
- Soft Tissue Sarcoma
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active